CannabisNewsWire Editorial Coverage: Restrictions in the United States on cannabidiol (CBD), an active ingredient in cannabis, appear likely to loosen over the next few months, creating opportunities for CBD production and distribution companies.
- CBD is an active ingredient with medical benefits but no “high”, or pyshcoactive effects.
- The Food and Drug Administration (FDA) has approved a CBD-based medicine for the first time.
- Companies are cultivating hemp to develop high yielding CBD plants.
Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is cultivating industrial hemp for CBD propagation at sites in the United States and Canada while continuting to develop and manfuacture CBD-based products for its hempSMART™ brand. Cronos Group, Inc. (NASDAQ: CRON) is expanding its global reach for cannabis products through deals covering the United States, Canada, Australia and Poland, as this sector of the economy goes global. CV Sciences, Inc. (OTC: CVSI) is providing a clean bill of health for its CBD wellness products. Terra Tech Corp. (OTC: TRTC) is providing advanced hydroponic growing systems that increase crop yields and reduce costs for CBD-oriented companies. Manufacturer Liberty Health Sciences (OTC: LHSIF) produces cannabis in facilities recently certified as meeting high standards for manufacturing.
FDA Leads the Way to Reclassify Cannabidiol
The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks. For the first time, the FDA has approved a medicine that uses cannabidiol (CBD) as its active ingredient. CBD is a compound that can be found in the hemp and cannabis plants, but unlike tetrahydrocannabinol (THC) it does not get users high.
Repeated studies have demonstrated the beneficial effects of cannabinoids. As a result, cannabis products have been approved for medical use in many states, but this is the first time that a cannabinoid-based CBD product has been approved at the federal level. This approval represents a softening of the federal government’s attitude. CBD was previously classified as a Schedule I drug by the Drug Enforcement Agency, but this body is now expected to change its stance within the next three months, allowing the possibility to manufacture products that would currently be banned on the national level. This possibility represents a huge moment for the CBD industry.
Better Plants for Better Health
One of the companies likely to benefit from this change is the Marijuana Company of America, Inc. (OTC: MCOA). The company is focused on the cultivation of industrial hemp and the manufacturing of hemp-derived CBD products, and is expanding its operations to better serve its growing market.
The most recent addition to the company’s operations is an industrial hemp cultivation site in Scio, Oregon. Created in collaboration with Global Hemp Group (GHG), this is a 109-acre site in the Willamette Valley. With its rich soil and pre-existing irrigation infrastructure, the valley provides an ideal location for an agricultural project that has already been home to cannabis cultivation in the past.
The Scio facility uses a mixture of cultivation practices. It has 19,000 square feet of greenhouse growing space under construction alongside fields for outdoor crops. This will allow the company to produce a steady supply of hemp all year, with high-yield plants ensuring a significant volume of output.
One of the main aims of the team working at Scio is to encourage plant strains that have a particularly high yield of CBD. Careful data collection and analysis are being used to assess the quality of plants and the effectiveness of techniques used to grow them. The expected change in the legal status of CBD in the United States will make it easier for MCOA to conduct research and cultivate CBD rich industrial hemp like at the Scio site, and for patients to have access to the products that come from it.
Working with Government to Improve Agriculture
MCOA and GHG are also collaborating on a similar project in New Brunswick, Canada, on a much larger scale. For this project, the two companies are working with the New Brunswick Department of Aquaculture, Agriculture and Fisheries (DAAF) to explore better approaches to growing hemp.
With markets for hemp and CBD reaching greater maturity, the DAAF has shown its faith in the future by awarding a grant of $10,750 to the joint MCOA and GHG venture in the region. These funds will be used on test projects for the current crop season, which will allow the companies to improve their cultivation techniques.
These government-funded tests are focused on three areas, two of which are looking at soil conditions to identify the best levels of nitrogen fertilizer for crops and whether soil acidity can be effectively adjusted using local supplies of slag lime. The third area of study is the European corn borer, a moth that damages crops and that has been a pest to farmers in the region. Damage from borers was found on hemp stalks last year, so the companies will be looking at the impact this damage could have on cultivation.
The latest technology is being used to ensure the success of these tests. A drone company has been employed to provide overviews of growth across hemp fields because the height of the stalks and density of cultivation makes assessment by other means difficult. With agricultural experiments underway in both Canada and the United States, MCOA has multiple opportunities to cultivate better CBD crops.
In New Brunswick, the two companies have created what they refer to as the Hemp Agro-Industrial Zone (HAIZ), where they are carrying out trials of hemp cultivation targeted at developing the industry in the province. By exploring cultivation techniques, ensuring a market for the product and providing consistent jobs for local farm workers, they aim to create a green-industry cluster specializing in hemp.
MCOA isn’t just a cultivation company. It is manufacturing its hemp crops into a wide range of products formulated to improve the well-being of customers.
Much of this work is carried out through hempSMART, the company’s most prominent consumer brand. HempSMART creates CBD-based wellness products and provides consumers with education about the potential benefits CBD may provide. Many consumers don’t understand the difference between CBD and THC products. Through hempSMART, MCOA is raising awareness while reaching out to a growing market.
The most recent release from hempSMART is the relaunch of its hempSMART Brain product. This version doubles the dose of CBD from the original, combining CBD oil with a blend of natural plant-based ingredients. Designed to maintain mental clarity, alertness, focus and concentration, as well as promote relaxation, restorative sleep, and the repair and regeneration of brain cells, hempSMART Brain is a flagship product that demonstrates MCOA’s wellness agenda. With the prospect of a change in the CBD compound’s legal status in the United States, companies such as MCOA will have more opportunities to develop and sell these types of products, spreading CBD-based wellness.
Growing Companies Profit from Changing Regulations
A range of companies in the cannabinoid sector will be in a position to profit from this change. Cronos Group, Inc. (NASDAQ: CRON) is demonstrating the global potential of cannabinoid products. The North American company already has a cross-border deal that allows it to make use of advances in both Canada and the United States. In addition, Cronos was recently granted a manufacturing license to produce cannabis-based products in Australia, and a new Polish distribution agreement will give the company a foothold in the European market.
CV Sciences, Inc. (OTC: CVSI) is firmly focused on the CBD sector. The company has two parts: a drug development division exploring novel CBD-based treatments and a consumer product division that manufactures, markets and sells the resulting products.
Some companies are focused on providing support and equipment for CBD cultivation. Terra Tech Corporation (OTC: TRTC) has created a hydroponic growing system that uses moving tables to increase yields by up to 30 percent while reducing costs by up to half. Its energy efficiency and recycling of waste water means that the company’s systems live up to the expectations of green-minded consumers.
Liberty Health Sciences (OTC: LHSIF) works in the medical cannabis market. As it acquires and operates U.S.-based cannabis companies, its aim is to produce safe, high-quality cannabis for patients. It has recently received Good Manufacturing Practice certification for its high standards of safety, consistency and quality.
Given the growing number of players in the cannabis market, a shift in the classification of CBD on a federal level could have a tremendous impact. For companies already focusing on CBD products, a huge opportunity for growth in the United States may be on the horizon.
For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.